Trial reportBritish journal of cancer2006
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.
Trial report in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Pooled it
- A fluorogenic probe for predicting treatment response in non-small cell lung cancer with EGFR-activating mutations.Nature communications · 2022Article
- Establishment and genomic characterizations of patient-derived esophageal squamous cell carcinoma xenograft models using biopsies for treatment optimization.Journal of translational medicine · 2018Article
- Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.Journal of Cancer · 2013Review
- First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments.Drugs · 2013Review
- Gefitinib in non small cell lung cancer.Journal of biomedicine & biotechnology · 2011Review
- Impact of biomarkers on non-small cell lung cancer treatment.Targeted oncology · 2010Review
- Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer.Lung Cancer (Auckland, N.Z.) · 2010Review
- The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement.Current oncology (Toronto, Ont.) · 2009Article
- A population-based study of gefitinib in patients with non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2009Article
- Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?Current oncology reports · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to evaluate the efficacy and tolerability of gefitinib ('IRESSA') in Japanese patients with previously untreated stage IV non-small-cell lung cancer (NSCLC). This was a multi-institutional phase II study. Thirty-four patients with previously untreated stage IV NSCLC were enrolled between May 2003 and September 2004. Gefitinib was administered orally 250 mg once a day and was continued until there was either disease progression or severe toxicity. Objective tumour response rate was 26.5% (95% confidence interval, 11.7-41.3%). Adverse events were generally mild (National Cancer Institute-Common Toxicity Criteria grade 1 or 2) and consisted mainly of skin rash, fatigue and liver dysfunction. No pulmonary toxicity was observed. The global health status revealed that there was no change in quality of life during the study. This study found that single-agent gefitinib is active and well tolerated in chemo-naive Japanese patients with advanced NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.